Survey of Non-Variceal Upper Gastro Intestinal Bleeding in Vietnamese Patients
Completed
- Conditions
- Re-bleeding in NVUGIB
- Registration Number
- NCT01292915
- Lead Sponsor
- AstraZeneca
- Brief Summary
The main aim of the study is to describes the outcomes of patients with Upper Gastrointestinal Bleed (UGIB) in a real-life setting. Additionally analyse assessed predictors of outcome, including the impact of hemostatic endoscopic and pharmacologic therapies.
- Detailed Description
MSD
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1044
Inclusion Criteria
- Adult patients (>=18yrs) admitted to the hospital, or inpatients admitted for another reason, presenting with overt non-variceal upper GI bleed manifesting as hematemesis/coffee ground vomiting, melena, hematochezia...
- Evidence that an upper GI endoscopy was performed
Exclusion Criteria
- GI bleeding not from NVUGIB
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Rebleeding (within 7 days from the Non-Variceal Upper Gastro Intestinal Bleeding (NVUGIB) episode) 7 days
- Secondary Outcome Measures
Name Time Method Surgery due to re-bleeding 7 days Mortality due to bleeding 7 days Rebleeding in high risk peptic ulcer patients 7 days
Trial Locations
- Locations (1)
Research Site
🇻🇳HoChiMinh City, Vietnam